IGF1 and Atrophy: Other anabolic agents, such as insulin-like growth factor-I (IGF-I) treatment8 and anabolic androgenic steroids,9 have some concerns on increased risks (drug resistance and cardiac events), limiting their therapeutic use for muscle atrophy.10